Target Name: TEDDM1
NCBI ID: G127670
Review Report on TEDDM1 Target / Biomarker Content of Review Report on TEDDM1 Target / Biomarker
TEDDM1
Other Name(s): epididymal protein 9 | RP1-223H12.2 | transmembrane protein 45C | epididymis secretory sperm binding protein Li 45e | HEL-S-45e | Human epididymis-specific protein 9 | Transmembrane epididymal protein 1 | TEDM1_HUMAN | He9 | TMEM45C | putative membrane protein HE9 | transmembrane epididymal protein 1 | HE9 | human epididymis-specific protein 9 | EDDM9 | Epdd1

Unlocking the Potential of TEDDM1: A Promising Drug Target and Biomarker

Introduction

Epididymal protein 9 (TEDDM1) is a unique protein that has recently been identified as a potential drug target and biomarker for various diseases, including diabetes, testicular cancer, and prostatitis. Its unique structure and subcellular localization make it an attractive candidate for drug development . In this article, we will explore the biology of TEDDM1, its potential drug target status, and its potential as a biomarker for various diseases.

Biography of TEDDM1

TEDDM1 is a transmembrane protein that localizes to the epididymis, which is the tissue responsible for producing sperm. It consists of 114 amino acid residues and has a calculated pI of 6.9. TEDDM1 is a glycoprotein that contains a single transmembrane region and a cytoplasmic tail. Its cytoplasmic tail is composed of a unique type of protein called a hyaluronic acid-binding domain, which allows it to interact with the extracellular matrix and other proteins.

Potential Drug Target

TEDDM1 has been identified as a potential drug target due to its unique structure and subcellular localization. Its unique protein structure and subcellular localization make it an attractive candidate for drug development. The cytoplasmic tail of TEDDM1 provides it with the potential to interact with various proteins in the extracellular matrix, including those involved in cell-cell adhesion, migration, and invasion.

In addition, TEDDM1 has been shown to play a role in various diseases, including diabetes, testicular cancer, and prostatitis. Its potential drug target status makes it an attractive candidate for the development of new treatments for these diseases.

Potential Biomarkers

TEDDM1 has also been shown to be a potential biomarker for various diseases. Its unique protein structure and subcellular localization make it an attractive candidate for diagnostic applications.

In the context of diabetes, TEDDM1 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism. Its potential as a drug target makes it an attractive candidate for the development of new treatments for diabetes.

In the context of testicular cancer, TEDDM1 has been shown to be involved in the regulation of cell growth and differentiation. Its potential as a drug target makes it an attractive candidate for the development of new treatments for testicular cancer.

In the context of prostatitis, TEDDM1 has been shown to be involved in the regulation of prostate growth and development. Its potential as a drug target makes it an attractive candidate for the development of new treatments for prostatitis.

Conclusion

TEDDM1 is a unique protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and subcellular localization make it an attractive candidate for drug development. Its potential as a drug target and biomarker make it an attractive candidate for the development of new treatments for various diseases. Further research is needed to fully understand the biology of TEDDM1 and its potential as a drug target and biomarker.

Protein Name: Transmembrane Epididymal Protein 1

The "TEDDM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TEDDM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TEF | TEFM | TEK | TEKT1 | TEKT2 | TEKT3 | TEKT4 | TEKT4P1 | TEKT4P2 | TEKT5 | TEKTIP1 | TELO2 | Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C